Real-World Achievement of Skin Clearance Targets and Improved Quality of Life With Risankizumab in Psoriasis Patients With Moderate Skin Involvement (BSA ≥ 3–10%). J of Skin. 2024;8(6):s421. doi:10.25251/skin.8.supp.421